AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32248637
Drug: One-session exposure
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-session exposure therapy
Trial: 32248637
Drug: Three-session exposure
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-session exposure therapy
Trial: 34605397
Drug: Preprocedural risk
RxNorm normalized name: Hep B, adolescent/high risk infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preprocedural risk score model based on five variables: age > 75 years, serum creatinine level ≥ 1.5 mg/dL, diabetes mellitus, hypotension, acute myocardial infarction.
Trial: 32703244
Drug: Partial Tinnitus
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial Tinnitus Retraining Therapy (Partial TRT)
Trial: 33561141
Drug: 50 mL
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mL of 0.9% sodium chloride (239 women)
Trial: 32459919
Drug: Remdesivir for
RxNorm normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remdesivir for 5 days (200 mg on day 1, 100 mg once daily thereafter)
Trial: 32459919
Drug: Remdesivir for
RxNorm normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remdesivir for 10 days (200 mg on day 1, 100 mg once daily thereafter)
Trial: 34256041
Drug: Resistance exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance exercise training (RET) for 16 weeks, performed twice weekly at low intensity
Trial: 32178953
Drug: Extraluminal bronchial
RxNorm normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extraluminal bronchial blocker (BB) for one-lung ventilation (OLV)
Trial: 37031887
Drug: Sacubitril/valsartan (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/valsartan (200 mg twice daily)
Trial: 35458138
Drug: Aqueous cinnamon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous cinnamon extract (6 g/100 mL)
Trial: 35458138
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (oral glucose tolerance test only)
Trial: 32565450
Drug: One-to-one befriending
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-to-one befriending by volunteers for people with ID (weekly visits for 6 months)
Trial: 33733588
Drug: Cisplatin-based chemotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based chemotherapy after radical hysterectomy
Trial: 35903950
Drug: l-arginine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-arginine (8 grams)
Trial: 32130359
Drug: Azithromycin (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (administered orally for 7 days)
Trial: 32130359
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered orally for 7 days)
Trial: 33753669
Drug: 0.145% sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.145% sodium fluoride gel in a custom tray during sleep
Trial: 33640423
Drug: Intensity modulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensity modulated radiation therapy (IMRT)
Trial: 32053276
Drug: Intravenous immunoglobulins
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulins (IVIg)
Trial: 33386662
Drug: Biological risk
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological risk score
Trial: 33386662
Drug: Biological score
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological score + predefined clinical score
Trial: 35371277
Drug: Routine rehabilitation
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine rehabilitation treatment
Trial: 33779742
Drug: Short-course radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course radiation therapy (TROG 01.04)
Trial: 33779742
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy omission (Dutch TME)
Trial: 32692270
Drug: High NK
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High NK cell count (≥184 × 10^6 cells/L) at baseline
Trial: 32692270
Drug: High NK
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High NK cell count (≥184 × 10^6 cells/L) before cycle 2
Trial: 35889947
Drug: Peanut group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut group (35 g of lightly salted dry-roasted peanuts prior to two main meals per day)
Trial: 36763358
Drug: Rivaroxaban 5
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban 5 mg
Trial: 35213496
Drug: Deep neuromuscular
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep neuromuscular block (NMB) with continuous infusion of rocuronium (0.5-1.0 mg kg⁻¹ h⁻¹)
Trial: 35213496
Drug: Moderate neuromuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate neuromuscular block (NMB) with continuous infusion of rocuronium (0.1-0.5 mg kg⁻¹ h⁻¹)
Trial: 35004776
Drug: Standard immunosuppression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard immunosuppression plus metformin (500 mg twice daily)
Trial: 35004776
Drug: Standard immunosuppression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard immunosuppression plus empagliflozin (25 mg once daily)
Trial: 32144074
Drug: HBV-AS04 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBV-AS04 vaccine (4 doses of 20 mcg each by intramuscular route)
Trial: 32144074
Drug: HBV-AS04 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBV-AS04 vaccine
Trial: 36245339
Drug: GP-delivered medication
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP-delivered medication review intervention
Trial: 32791589
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with standardized dust mite vaccine for 2 years
Trial: 32791589
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (placebo and conventional drug treatment)
Trial: 36199765
Drug: Oral drug
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral drug therapy and small incision reduction and suture
Trial: 32274665
Drug: Treatment-induced symptoms
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-induced symptoms (vaginal dryness, sleep disturbances, bone or joint pain) at 6 months
Trial: 33188417
Drug: Whole grain
RxNorm normalized name: Whole grain barley
DrugBank: Barley (DB10506)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole grain wheat (WGW) intervention (98 g/d)
Trial: 33188417
Drug: Refined wheat
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refined wheat (RW) intervention (98 g/d)
Trial: 33883461
Drug: Combination BP
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination BP therapy with perindopril and indapamide
Trial: 32802868
Drug: SL implants
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SL implants (implants with an augmented depth of the threads)
Trial: 32802868
Drug: SY implants
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SY implants (implants with standard threads)
Trial: 32802868
Drug: Both SL
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both SL and SY implants
Trial: 32384160
Drug: Systemic patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic patient-controlled analgesia (PCA) or regional analgesic techniques
Trial: 35970671
Drug: Erector spinae
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erector spinae plane (ESP) block with 25 mL of bupivacaine plus 0.5 μg/kg of dexmedetomidine
Trial: 35970671
Drug: Conventional intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional intravenous analgesia with a 0.7 μg/kg dexmedetomidine bolus and a 0.3 μg/kg infusion
Trial: 33025616
Drug: Fenugreek extract
RxNorm normalized name: Fenugreek extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenugreek extract (FHE) 250 mg × 2/day for 42 days
Trial: 34017263
Drug: Norepinephrine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine treatment
Trial: 33852919
Drug: Mycobacterium w
RxNorm normalized name: Mycobacterium W Vaccine
DrugBank: Mycobacterium w. Vaccine (DB15798)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mycobacterium w (Mw) 0.3 mL/d intradermally for 3 days
Trial: 35639720
Drug: Citicoline 1gm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citicoline 1gm BD intravenously for three days, followed by oral citicoline 1gm BD for 39 days.
Trial: 35639720
Drug: Placebo (100ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (100ml intravenous normal saline for three days, followed by multivitamin tablet BD for 39 days).
Trial: 33147257
Drug: G-CSF post-ASCT
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF post-ASCT
Trial: 33147257
Drug: Avoided G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avoided G-CSF post-ASCT
Trial: 33147257
Drug: Avoided G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avoided G-CSF and added corticosteroid prophylaxis post-ASCT
Trial: 33147257
Drug: G-CSF avoidance
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF avoidance plus corticosteroids
Trial: 36116756
Drug: Mindfulness-based interventions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based interventions (up to 3 sequential interventions based on non-response)
Trial: 33751297
Drug: Overall (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall (50 implants)
Trial: 32134114
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated hepatitis A virus vaccine (HA‐L)
Trial: 34838132
Drug: Intravenous thyroxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thyroxine for at least 12 hours
Trial: 32424949
Drug: Xylazine continuous
RxNorm normalized name: Xylazine
DrugBank: Xylazine (DB11477)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylazine continuous rate infusion (CRI) at 1 mg/kg/hr for 2, 4, and 6 hours after an initial bolus of 0.5 mg/kg
Trial: 32424949
Drug: Xylazine continuous
RxNorm normalized name: Xylazine
DrugBank: Xylazine (DB11477)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylazine continuous rate infusion (CRI)
Trial: 35260787
Drug: tolcapone (COMT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolcapone (COMT inhibitor)
Trial: 35468752
Drug: Contoura treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contoura treatment
Trial: 35468752
Drug: Custom‐Q treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Custom‐Q treatment
Trial: 34241629
Drug: Apatinib (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib (500 mg orally once daily on days 1 to 21) plus SOX (S‐1: 40‐60 mg orally twice daily on days 1 to 14; oxaliplatin: 130 mg/m2 intravenously on day 1) every 3 weeks for 2 to 5 cycles
Trial: 33326878
Drug: Supportive Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive Care Therapy (SCT)
Trial: 34925003
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine (TCM) prescriptions
Trial: 35492074
Drug: Morphine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine + Ketamine (Mor + Ket)
Trial: 35496368
Drug: Lidocaine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1.5 mg/kg bolus completed 10 min before anesthesia induction followed by an infusion at 2.0 mg/kg/h)
Trial: 35496368
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (volume-matched at the same infusion rate)
Trial: 32105678
Drug: Valaciclovir (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valaciclovir (8 g/d) given from the diagnosis of primary infection up to amniocentesis
Trial: 32105678
Drug: Oral valaciclovir
RxNorm normalized name: valacyclovir Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral valaciclovir (8 g/d) given to pregnant women with a mildly symptomatic fetus
Trial: 32397821
Drug: Pika Pamoja
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pika Pamoja (treatment)
Trial: 33269530
Drug: semaglutide 2.4
RxNorm normalized name: semaglutide 2.4 MG in 0.75 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: semaglutide 2.4 mg
Trial: 36905345
Drug: semaglutide 1.7
RxNorm normalized name: semaglutide 1.7 MG in 0.75 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: semaglutide 1.7 mg
Trial: 39514025
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg tamoxifen
Trial: 32081901
Drug: Dextromethorphan (NMDA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (NMDA receptor antagonist)
Trial: 33854132
Drug: Perampanel (AMPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perampanel (AMPA receptor antagonist)
Trial: 33854132
Drug: Nimodipine (L-type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine (L-type voltage-gated calcium channel blocker)
Trial: 32028996
Drug: Mass spectrometry
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass spectrometry identification of spots from the 2‐DE gel of D. hirsuta
Trial: 33590901
Drug: Supportive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive treatment
Trial: 34237668
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment and follow-up (Control)
Trial: 35792064
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus chemotherapy (200 mg Q3W for up to 35 cycles + chemotherapy: paclitaxel 175 mg/m2 + cisplatin 50 mg/m2 or carboplatin AUC 5)
Trial: 35792064
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus chemotherapy (same chemotherapy regimen)
Trial: 34343623
Drug: Preoperative lateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative lateral quadratus lumborum block (40 mL, ropivacaine 0.25%)
Trial: 34195765
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia with postoperative intravenous analgesia
Trial: 32001384
Drug: Allograft bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allograft bone (30 g/level)
Trial: 35315885
Drug: Prophylactic 40%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic 40% dextrose gel (n=681)
Trial: 35315885
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel (n=678)
Trial: 35315885
Drug: Prophylactic 40%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic 40% dextrose gel
Trial: 33053024
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus dexamethasone (20mg IV once daily for 5 days, then 10mg IV once daily for additional 5 days or until ICU discharge)
Trial: 33053024
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment without dexamethasone (Control Group)
Trial: 36442498
Drug: Vi polysaccharide‐tetanus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vi polysaccharide‐tetanus toxoid conjugate vaccine (Vi‐TT)
Trial: 35598000
Drug: Structured educational
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured educational intervention based on the rational perception of postoperative pain and discomfort (anchoring and improved pain scale), and the proper use of analgesics
Trial: 33723790
Drug: Synolis VA
RxNorm normalized name: VP/VA COPOLYMER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synolis VA (80 mg hyaluronic acid and 160 mg sorbitol)
Trial: 33723790
Drug: Synvisc-One (48
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synvisc-One (48 mg hylan GF-20)
Trial: 33989539
Drug: Tri-antigenic hepatitis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tri-antigenic hepatitis B vaccine (TAV) - 10 μg, administered intramuscularly on days 0, 28, and 168.
Trial: 33989539
Drug: Mono-antigenic hepatitis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mono-antigenic hepatitis B vaccine (MAV) - 20 μg, administered intramuscularly on days 0, 28, and 168.
Trial: 33374575
Drug: Topical gel
RxNorm normalized name: Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gel containing diclofenac sodium, methyl salicylate, and lyophilized Calendula officinalis
Trial: 34082075
Drug: Daily self-weighing
RxNorm normalized name: DAILY SELF DISCOVERY SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily self-weighing (DSW) with instruction to weigh daily and provision of a web-enabled digital scale with graphical weight feedback
Trial: 32718912
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg plus clopidogrel 75 mg daily
Trial: 32718912
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg plus ticagrelor 90 mg twice daily
Trial: 32738349
Drug: Methylene blue-assisted
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue-assisted photodynamic therapy (PDT) with FMPD
Trial: 35475696
Drug: Automated insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Automated insulin delivery systems
Trial: 34534923
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine 4 mg/kg via local infiltration at the end of spine surgery (age group 1)
Trial: 34534923
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine 4 mg/kg via local infiltration at the end of spine or cardiac surgery (age group 2)
Trial: 34534923
Drug: Bupivacaine hydrochloride
RxNorm normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine hydrochloride (HCl) 2 mg/kg via local infiltration at the end of spine surgery (age group 1)
Trial: 33094466
Drug: Intravenous high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous high-dose vitamin C (3.0 g dissolved in 5% dextrose, 100 ml/time, 2 times/day)
Trial: 33094466
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (routine therapy with intravenous drip of 5% dextrose and placebo, 100 ml/time, 2 times/day)
Trial: 33094466
Drug: Intravenous high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous high-dose vitamin C
Trial: 33124791
Drug: Statins (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statins (10 mg of rosuvastatin)
Trial: 33602197
Drug: SRP using
RxNorm normalized name: SRP 299
DrugBank: SRP 299 (DB05440)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP using EGCG solution as coolant
Trial: 32333328
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg/Caffeine 100 mg FDC
Trial: 35601970
Drug: Temozolomide (TMZ)
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide (TMZ) administered in the morning (AM) before 10 am
Trial: 35601970
Drug: Temozolomide (TMZ)
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide (TMZ) administered in the evening (PM) after 8 pm
Trial: 33920642
Drug: Nasal steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal steroid spray + BSE
Trial: 33920642
Drug: Nasal steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal steroid spray + placebo tablet
Trial: 33920642
Drug: Saline nasal
RxNorm normalized name: Ayr Saline Nasal
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline nasal spray + BSE
Trial: 33920642
Drug: Saline nasal
RxNorm normalized name: Ayr Saline Nasal
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline nasal spray + placebo tablet